PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumorsMónica Tang, Michael Friedländer, Rachel O’Connell et al.|Gynecologic Oncology|2019Cited by 88
Selective Nucleic Acid Removal via Exclusion (SNARE): Capturing mRNA and DNA from a Single SampleLindsay N. Strotman, David J. Beebe, Rachel O’Connell et al.|Analytical Chemistry|2013Cited by 45
Therapeutic mammaplasty is a safe and effective alternative to mastectomy with or without immediate breast reconstructionShelley Potter, Matthew Gardiner, R. Douglas Macmillan et al.|British journal of surgery|2020Cited by 40
PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progressionPeey‐Sei Kok, Rachel O’Connell, Peter Grant et al.|Journal of Gynecologic Oncology|2019Cited by 26
Paragon (ANZGOG-0903)Anthony Bonaventura, Michael Friedländer, Rachel O’Connell et al.|International Journal of Gynecological Cancer|2017Cited by 22